MAPT and amyotrophic lateral sclerosis: The most straightforward explanation is that this effect may reflect the relatively more homogeneous TDP‐43 pathology driving ALS‐FTD [8], in contrast to the more heterogeneous pathological spectrum of the bvFTD group, where the impact of TDP‐43 could be attenuated by the inclusion of patients with FTLD‐tau [10].